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Neurological recoverya b s t r a c t
The pathophysiology of spinal cord injury (SCI) involves post-traumatic inﬂammation and glial scarring
which interfere with repair and recovery. Self-assembling peptides (SAPs) are molecules designed for tis-
sue engineering. Here, we tested the performance of K2(QL)6K2 (QL6), a SAP that attenuates inﬂammation
and glial scarring, and facilitates functional recovery. We injected QL6 into the spinal cord tissue of rats
24 h after clip compression SCI. QL6 led to a signiﬁcant reduction in post-traumatic apoptosis, inﬂamma-
tion and astrogliosis. It also resulted in signiﬁcant tissue preservation as determined by quantitative his-
tomorphometry. Furthermore, QL6 promoted axonal preservation/regeneration, demonstrated by BDA
anterograde and Fluorogold retrograde tracing. In vitro experiments found that a QL6 scaffold enhanced
neuronal differentiation and suppressed astrocytic development. The electrophysiology conﬁrmed that
QL6 led to signiﬁcant functional improvement of axons, including increased conduction velocity, reduced
refractoriness and enhanced high-frequency conduction. These neuroanatomical and electrophysiological
improvements were associated with signiﬁcant neurobehavioral recovery as assessed by the Basso–Beat-
tie–Bresnahan technique. As the ﬁrst detailed examination of the pathophysiological properties of QL6 in
SCI, this work reveals the therapeutic potential of SAPs, and may suggest an approach for the reconstruc-
tion of the injured spinal cord.
 2013 The Authors. Acta Materialia Inc. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
Neurotrauma, including spinal cord injury (SCI), is a leading
cause of neurological disability and death. The pathophysiology
of SCI involves a primary mechanical injury followed by a series
of secondary molecular and cellular changes [1]. The inherent chal-
lenge of developing therapies aimed at treating SCI is rooted in the
complexity of its pathobiology, which includes invasion of inﬂam-
matory agents, ongoing apoptosis of neural cells, demyelination,
formation of cavities or cysts, glial scarring and the loss of complex
neural circuitry [2]. The combined presence of cavitation and glialscarring acts as a physical and chemical barrier to repair, plasticity
and regeneration. Current therapeutic strategies for acute SCI are
chieﬂy aimed at preventing tissue loss with pharmacological
agents. No interventions have yet been developed to reconstruct
post-traumatic cyst cavities. Hence, it is attractive to develop a tis-
sue-engineered scaffold which could act as a bridge for endoge-
nous cell migration, axonal elongation and plasticity.
In the past decade, self-assembling peptides (SAPs) have been
developed for tissue engineering and protein delivery [3]. Syn-
thetic SAPs can self-assemble into nanoﬁbers in situ under physio-
logical conditions, without apparent immune response [4]. These
properties make SAPs appealing for application in SCI because they
can be injected directly into the lesion site, thus minimizing the
damage to the cord which can occur with the implantation of solid
scaffolds. Liquid SAPs can readily ﬁll the cavities, regardless of their
size and shape, and become integrated with host tissue after self-
assembling to a hydrogel. The use of SAPs is a novel approach in
providing a nanoﬁbrillar biocompatible structure, similar to the
native extracellular matrix. This direct contact between nanoﬁbers
and the extracellular matrix may be critical in facilitating
8076 Y. Liu et al. / Acta Biomaterialia 9 (2013) 8075–8088cell–scaffold interaction [5,6]. SAP nanoﬁber scaffolds have become
increasingly important, not only in studying the three-dimensional
microenvironment, but also in developing approaches for a wide
range of innovative medical technologies, including regenerative
medicine [5]. It has been reported that after SCI, in vivo treatment
with IKVAV containing SAP amphiphile (IKVAV PA) reduces
astrogliosis and cell death and promotes regeneration of both
descending motor ﬁbers and ascending sensory ﬁbers [7]. In this
study, it was necessary to promote PA bioactivity by incorporating
the neurite-promoting laminin epitope IKVAV into the molecular
design of the scaffold. Another SAP substance found in the litera-
ture is RADA16-I (Ac-RADARADARADARADA-CONH2), this peptide
was found to bridge the injured spinal cord, elicit axon regenera-
tion [8] and reduce the glial reaction and inﬂammation in sur-
rounding brain tissue [9]. In a recent paper, a bone marrow
homing peptide, RADA16-I SAP, functionalized by combining with
a bioactive peptide, PFSSTKT (BMHP1), was found to induce a
favorable matrix remodeling process and provide physical and tro-
phic support to spinal cord tissue regrowth, cellular inﬁltration and
axon regeneration/sprouting [10]. However, RADA16-I has a pH of
3–4; when applied directly onto nervous tissue, this degree of acid-
ity may cause tissue damage. Guo et al. reported that untreated
RADA16-I with low pH values could be detrimental in that they
cause inﬂammation in the host spinal cord tissue, creating distinct
gaps and cysts surrounding the implants [8]. Therefore, there are
certain limitations associated with the use of RADA16-I, notably
its intrinsically low pH and the resultant need for prebuffering to
counteract the acidity of the SAP.
K2(QL)6K2 (QL6) is a novel SAP introduced by Dong et al. [11]
and provided by Covidien. It is important to note that QL6 self-
assembles into b-sheets at neutral pH, a feature that is rare among
peptides, which generally form insoluble b-sheet assemblies [11].
The present study was designed to determine the effects of QL6
in the reconstruction of the injured spinal cord when administered
at the clinically relevant time point of 24 h post-SCI. We reported
that, without any bioactive adjunct, QL6 can provide favorable sup-
port for neuronal growth and functional repair post-SCI, as shown
by combined neuroanatomical, electrophysiological and neurobe-
havioral data. These observations suggest that the SAP QL6 is a
promising biomaterial for central nervous system injury.
2. Materials and methods
2.1. Animal SCI and intraspinal microinjection
All animal experiments were conducted with approval from the
Animal Care Committee, University Health Network (Toronto, Can-
ada). The aneurysm clip compression/contusion model of SCI used
in our laboratory has been characterized extensively and described
previously [12,13]. Brieﬂy, adult female Wistar rats (250–300 g;
Charles River, Montreal, Canada) received laminectomies of mid-
thoracic vertebral segments T6–T7. A modiﬁed clip calibrated to
a closing force of 35 g was applied extradurally to the cord for a
duration of 1 min. The animals were divided into two groups in a
randomized and blinded manner, namely the QL6 treatment group
and a saline control group. We chose a QL6 concentration of 1% (w/
v) for gel formation that can mimic extracellular matrix [7,11]. Ge-
lain et al. [14] reported that a SAP concentration of 1% (w/v)
yielded a hydrogel scaffold stiffness similar to that of the spinal
cord. The opacity and mechanical stiffness of the hydrogels in-
crease with increasing peptide concentration. 1% (w/v) peptide
concentration demonstrated a medium ﬁber density under scan-
ning electron microscopy observation, which could have a stable
nanostructure (unpublished data).
Using a stereotaxic frame and glass capillary needle connected
to a Hamilton microsyringe, a total of 10 ll was injected into thedorsal spinal cord 24 h after SCI. Two intraspinal injections were
made bilaterally rostral and caudal to the injury site starting at
2 mm below the dorsal surface and then at intervals of 0.5 mm
(three sites), with 1.67 ll being injected at each interval amount-
ing to a total dose of 5 ll at each stump (Fig. 1B). The injection rate
was 0.5 ll per minute and, at the end of injection, the capillary was
left in the cord for at least 1 min to allow diffusion from the injec-
tion site.
2.2. Electron microscopic characterization of the scaffolds
2.2.1. Transmission electron microscopy (TEM)
QL6 samples were applied to carbon-coated copper grids, and
were allowed to adsorb for 1 min. The grids were then stained by
2% phosphotungstic acid for 30 s for negative staining. The stained
grids were allowed to air dry before imaging. Electron microscopy
images were obtained using a Hitachi H-7000 transmission elec-
tron microscope at an 75 kV accelerating voltage.
2.2.2. Scanning electron microscopy (SEM)
Samples were soaked in 5% glutaraldehyde at 4 C for 2 h,
slowly dehydrated in 10% increment steps of ethanol for 5 min
each, and placed in a pressurized liquid CO2 siphon for 1 h using
a CO2 critical point dryer. Scaffolds were coated with gold with a
sputter coater, and images were taken with a Hitachi S-3400N
scanning electron microscope.
2.3. Histological processing and tissue sparing assessment
Animals were perfused transcardially with 4% paraformalde-
hyde in 0.1 M phosphate-buffered saline (PBS). The tissues were
then cryoprotected in 25% sucrose in PBS. A 2 cm length of the
spinal cord centered at the injury site was embedded in tissue-
embedding medium. The injured segment was snap frozen and
sectioned on a cryostat (Leica CM3050S). Serial spinal cord sections
at 500 lm intervals were stained with myelin-selective pigment
luxol fast blue (LFB) and the cellular stain hematoxylin–eosin
(HE) to identify the injury epicenter.
2.3.1. Assessment of tissue sparing at the injury site
Tissue sparing was analyzed 8 weeks after SCI, at the center of
the lesion, 2 mm rostral and 2 mm caudal to the epicenter. Sections
were stained with LFB-HE. The measurements were carried out on
coded slides using ImageJ software (NIH). Cross-sectional residual
tissue was normalized with respect to total cross-sectional area
and the areas were calculated every 500 lm within the rostrocau-
dal boundaries of the injury site.
2.4. GFAP and Iba-1immunohistochemical procedures and image
analysis
The following primary antibodies were used: mouse anti-glial
ﬁbrillary acidic protein (GFAP) (1:500; Chemicon International,
Inc., Temecula, CA) for astrocytes, mouse anti-Iba-1 (1:500, Wako,
Japan) for macrophages/microglia [15]. The sections were rinsed
three times in PBS after primary antibody incubation and incu-
bated with ﬂuorescent Alexa 568 goat anti-mouse/rabbit second-
ary antibody (1:400; Invitrogen, Burlington, ON) for 1 h. The
sections were rinsed three times with PBS and coverslipped with
Mowiol mounting medium containing DAPI (Vector Laboratories,
Inc., Burlingame, ON) to counterstain the nuclei. The images were
taken using a Leica epiﬂuorescence microscope.
For immunodensity measurements of GFAP and Iba-1, four sec-
tions were selected at the epicenter, as well as at 1 and 2 mm (two
rostral and two caudal) from the injury epicenter in each animal.
We photographed the entire transverse section at 10 primary
Fig. 1. Delivery of the SAP QL6 into the injured rat spinal cord. (A1) TEM image of QL6 peptide in water. Scale bar: 100 nm. (A2) SEM image of QL6 nanoﬁber scaffold at 1% (w/
v) peptide concentration assembled in PBS solution at 2 h. Scale bar: 0.2 lm. (B) Two intraspinal injections were made bilaterally rostral and caudal to the injury site for a
total dose of 10 ll. (C) Longitudinal sections of rat spinal cord obtained at the injury site 1 week and 8 weeks after compression injury and QL6-FITC injection. The QL6 was
successfully injected into the cord. It aggregated in the epicenter and diffused rostrocaudally into the penumbra at 1 week, and almost biodegraded at 8 weeks. Scale bar:
600 lm.
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Each scan was performed using identical laser power, gain and off-
set values. The immunodensity of each image was measured using
NIH ImageJ software. The relative ﬂuorescence values were ex-
pressed as fold increases over the baseline (uninjured cord). We di-
vided the integrated density by the sample area to calculate the
mean density per unit area. This calculation was performed to
compensate for the different sizes of the region of interest in the
spinal cord. The ﬁnal immunodensity values were then averaged
for each group [16].
2.5. Apoptotic cell death and quantiﬁcation
An in situ terminal-deoxy-transferase mediated dUTP nick end-
labeling (TUNEL) apoptosis kit (Chemicon International, Inc.,
Temecula, CA) was used to label apoptotic cells as described in
the manufacturer’s instructions. Brieﬂy, sections were rinsed three
times in PBS and, once in equilibration buffer, followed by applica-
tion of terminal deoxynucleotidyl transferase enzyme for 1 h in ahumidiﬁed chamber at 37 C. To label apoptotic cells, an anti-
digoxigenin–ﬂuorescein conjugate solution was applied to sections
for 1 h at room temperature in the dark. Slides were mounted and
coverslipped with Mowiol containing DAPI. Anti-cleaved caspase-3
(1:200; Cell Signaling Technology, Danvers, MA) immunohisto-
chemistry was also used to detect and conﬁrm apoptosis. The
images of each section were taken using a Leica microscope with
StereoInvestigator. The numbers of TUNEL and cleaved caspase-
3-positive nuclei were counted at the epicenter, 1 and 2 mm (ros-
tral and caudal, four sections were selected at each site) from the
injury epicenter. The whole section was counted to include all
apoptotic nuclei visible in each tissue section.2.6. BDA anterograde tracing of the corticospinal tract
One week before being killed, rats underwent anterograde trac-
ing of the corticospinal tract (CST) with biotinylated dextran amine
(BDA). Under anesthesia, rats were positioned in a stereotaxic
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jected unilaterally into the left sensorimotor cortex at eight sites
(0.5 ll per site) following a previously described method [16]. Six
transverse sections per animal at 2, 4 and 8 mm (2 sections per
site) to the injury site were selected for immunohistochemical pro-
cessing against BDA. The sections were incubated with the follow-
ing reagents: 0.03% hydrogen peroxide (H2O2) in absolute
methanol for 30 min at 4 C, Vectastain AB (ABC Elite Kit, Vector
Laboratories) in PBS containing 0.3% Triton X according to manu-
facturer’s instructions for 2 h. Tissues were then incubated for
10 min with the NovaRED substrate kit (Vector Laboratories) for
visualization of antibody binding. The slides were then dehydrated
through an alcohol series, cleared in xylene and coverslipped.
We photographed the entire horizontal section at 10 primary
objective using tiling and stitching software (StereoInvestigator).
Using ImageJ Software (NIH), we measured the integrated density
of BDA labeling in a traced area. Background intensity from an area
with no BDA positive staining was subtracted from the intensity
value to correct for nonspeciﬁc reactions. The density values at
the BDA labeled region were normalized to the values obtained
from control cord.
2.7. Fluorogold (FG) retrograde tracing and neuronal counting
Animals underwent complete spinal cord transection at the le-
vel of T10 under anesthesia, for introduction of the retrograde ax-
onal tracer ﬂuorogold (FG; Fluorochrome, LLC, Denver, CO) as
described in a previous publication from our laboratory [17]. In
brief, FG was dissolved to a ﬁnal concentration of 4% (w/v) in PBS
and ﬁlter-sterilized. Sterile 5 mm  5 mm  2 mm gel foam pled-
gets were immersed in the FG solution and then placed into the
transection sites. One week subsequent to FG implantation, the
brain was extracted after a transcardial perfusion ﬁxation. The
brains were cut on a cryostat (Leica model CM3050) in 40 lm coro-
nal sections, from the caudal extent of the medulla to the rostral
extent of the third ventricle. Identiﬁcation of target regions, i.e.
red nucleus and vestibular nuclei, was performed under Zeiss
510 laser confocal microscope.
To assess numbers of neurons labeled by retrograde tracing,
every ﬁfth section of the embedded brainstem was identiﬁed
according to the rat brain atlas of Paxinos and Watson (1998).
The total number of FG-labeled neurons was calculated for each re-
gion according to the following formula: (rostral to caudal length
of region in lm/40 lm)  labeled neuron sum/number of sections
analyzed for the region, to obtain the ﬁnal summed number of la-
beled neurons for each region in each animal. For these proﬁle
counts, the Abercrombie formula [18] was applied to correct for
overcounting.
2.8. Adult neural precursor cell (NPC) seeding on QL6 and cell
differentiation assay
NPCs were harvested from the subventricular zone of adult
C57BL/6 mice using a previously described method [19]. Primary
neurospheres were present approximately 7 days after initial isola-
tion and passaged weekly by mechanical dissociation and were
seeded into serum-free medium containing epidermal and ﬁbro-
blast growth factors. For the in vitro analysis of cell differentiation,
neurospheres were differentiated by removing growth factors from
media and adding 1% fetal bovine serum (FBS). The QL6 peptide
was diluted with sterile distilled water, and mixed in a 1:1 volume
ratio with 8% glucose in order to cope with the cellular osmolarity.
QL6 SAP was assembled by adding basal medium 2 h before seed-
ing cells. We coated a multichamber slide with matrigel (BD Biosci-
ences, Mississauga, ON) to serve as a control. 2  104 cells per well
were plated on the top surface of 1% QL6 SAP or matrigel.The cultures were then grown for 7 days, at which time they
were ﬁxed with 4% paraformaldehyde. The cells were blocked
and double labeled with the following primary antibodies: mouse
against bIII-tubulin (1:500, Covance, Princeton, NJ) for neurons,
rabbit anti-GFAP (1:500; Chemicon) for astrocytes. Alexa 488 goat
anti-mouse and 568 goat anti-rabbit (1:400; Invitrogen) secondary
antibodies were used to probe the primary antibodies. The images
were taken using a Zeiss 510 laser confocal microscope.
2.9. In vivo electrophysiology
Motor-evoked potential (MEPs) recording: MEPs were recorded
in vivo to assess the physiological integrity of spinal cord. This ap-
proach has been extensively used in our laboratory in rodent mod-
els of SCI. In vivo recordings of MEPs were recorded from the
injured rats that had received QL6 treatment and compared to
recordings from a group of injured control rats at 8 weeks post-in-
jury (n = 6 per group). For MEPs, rats were under light isoﬂuorane
anesthesia (<1%), and recordings were obtained from hindlimb bi-
ceps femoris muscle. A pair of stainless steel subdermal needle
electrodes was inserted into the muscle. Recordings were acquired
using Keypoint Portable (Dantec Biomed, Denmark). A ground elec-
trode was placed under the skin between the recording and stim-
ulating electrodes. A 2 mA square pulse stimulation of 0.1 ms at a
rate of 0.13 Hz was applied to the midline of the cervical spinal
cord. The amplitude was determined by the difference between
the positive peak and negative peak. The latency was calculated
as the time from the start of the stimulus artifact to the ﬁrst prom-
inent peak. For individual rats, the mean peak amplitude and la-
tency was measured from the averaged traces from 200 sweeps.
2.10. In vitro electrophysiology
The dissection procedures were generally similar to those de-
scribed in earlier publications from our laboratory [17,19–21].
The animals were anesthetized, and the spine from the upper cer-
vical to lower lumbar levels was quickly removed, and the spinal
cord extruded by applying pressurized ice-cold artiﬁcial cerebro-
spinal ﬂuid (ACSF) to the rostral end of the vertebral canal via a
tightly ﬁtting pipette tip connected to a syringe. The subsequent
dissection, performed in oxygenated ice-cold ACSF, included
removing the meninges and spinal roots (if left after extrusion),
longitudinal hemisection of the cord and dissection of dorsal, as
well as lateral and ventral white matter. The dorsal white matter
strips were incubated in oxygenated ACSF for at least 1 h before
recording.
Suction electrodes were applied to record compound action
potentials (CAPs) from the spinal cord white matter [22]. This tech-
nique provides an excellent seal, and a stable resistance, both of
which are essential to achieve consistent CAP recordings with suc-
tion techniques [23]. A bipolar electrode, made of polyimide-insu-
lated stainless steel wires (outside diameter 0.125 mm, Plastics
One, Roanoka, VA), was used for stimulation of the dorsal column.
The stimulation and recording sites were approximately 5 mm
apart. The stimulating pulse current (0.1 ms in duration) was ap-
plied at 15 s intervals from the SIU-PSIV6 stimulus isolation unit
of a Grass S88 stimulator. The recording electrodes were connected
to the head stage of an Axoprobe 1A ampliﬁer (Axon Instruments)
via an Ag/AgCl electrode. The signals were ampliﬁed 100 in DC
mode (10 by Axoprobe 1A and then 10 by a custom-made DC
preampliﬁer), processed using Digidata 1200, stored on a PC and
analyzed using pClamp 10 software (Axon Instruments/Molecular
Devices, USA).
CAP recordings were analyzed according to their baseline-to-
peak amplitude, width, refractory period with pair pulse stimula-
tion. The maximal amplitude of the CAPs was recorded at supra-
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was examined by stimulating the cord by pair pulses with different
intervals (starting from 0.5 ms with an increment of 0.5 ms), and
by examining the recovery of the second CAP in comparison to
the ﬁrst one. To examine the ability of spinal cord axons to conduct
signals at high frequency, the cord was stimulated with 20, 50 and
100 Hz (100 pulses in total), respectively. The amplitude of the last
CAP was expressed as a percentage of the ﬁrst CAP in the train, a
method used previously by our laboratory [24] to estimate the fa-
tigue of the axons induced by high-frequency stimulation (HFS).
2.11. Neurobehavioral testing
BBB open-ﬁeld locomotor score: locomotor recovery of the ani-
mals was assessed by two independent observers using the 21-
point Basso, Beattie and Bresnahan (BBB) open-ﬁeld locomotor
score [25] from 1 to 8 weeks after SCI. The BBB scale was used to
assess hindlimb locomotor recovery including joint movements,
stepping ability, coordination and trunk stability. Testing was done
every week on a blinded basis and the duration of each session was
4 min per rat. Scores were averaged across both the right and left
hindlimbs to arrive at a ﬁnal motor recovery score for each week
of testing.
2.12. Statistical analysis
Data were analyzed with SigmaStat (Systat Software). For com-
parison of groups over time (BBB behavioral testing) or distance
(tissue sparing), we used two-way analysis of variance (ANOVA)
with repeated measures, followed by the post hoc Bonferroni test.
For neuroanatomical studies, statistical analyses of intensity mea-
surements and cell counts were tested by Student’s t tests where
two groups were compared.3. Results
3.1. Biodistribution and biodegradation of QL6 in injured spinal cord
To visualize the structure of the self-assembled QL6 nanoﬁbers,
we dissolved QL6 in Milli-Q water or PBS. Since the gelation of SAP
is initiated by salt concentration, QL6 should not be combined with
salt-containing buffers until gelation is desired. TEM was used to
show the morphology of QL6 dissolved in water, the structure of
a single molecule indicated that the peptide is not contaminated
by other ions. When QL6 was dissolved in PBS and was allowed
to assemble for 2 h, SEM demonstrated the network scaffold of
QL6 nanoﬁber (Fig. 1A).
One advantage of SAPs is their ability to self-assemble into
nanoﬁbers when injected into tissue. To evaluate the delivery
and biodistribution of the QL6 in vivo, at 24 h after SCI, the lesion
site was injected with a ﬂuorescent derivative of the QL6 (QL6-FITC
was mixed in a 1:9 volume ratio with QL6), and the rats were killed
at 1, 4, 6 and 8 weeks after injection. Images taken from 1 week
after injection show excellent distribution of the QL6 scaffold in
the injured cord, particularly rostrocaudally into the perilesional
‘‘penumbra’’ zone, where we observed that QL6 diffused for
approximately 1 cm centered on the injury epicenter with our
injection method (Fig. 1B). The QL6 scaffold degraded gradually
over time. At 8 weeks post-injection, although QL6 ﬂuorescent is
still present, most has biodegraded (Fig. 1C).
3.2. QL6 reduces astrogliosis and inﬂammation
One of the major obstacles to neuronal regeneration after SCI is
glial scarring that occurs in part as a result of reactive astrogliosis,which has been suggested to be involved in neurotoxicity and
inﬂammation [26]. We examined whether the QL6 affected the
population of reactive astrocytes and inﬂammation around the
SCI lesion. Cellular hypertrophy and increases in GFAP are the hall-
marks of astrocyte reactivity and occur after SCI. Using immuno-
histochemical analyses, we examined the expression of GFAP and
Iba1 as markers for reactive astrocytes and macrophages/microg-
lia, respectively. We focused on the lesional and perilesional areas.
At 1 week after SCI, GFAP and Iba1 immunohistochemistry re-
vealed no apparent difference between the injected control and
QL6-injected groups. Eight weeks post-SCI, interestingly, there
were obvious reductions in astrogliosis and inﬂammation in the
QL6-treated animals (Fig. 2A, B). GFAP staining revealed a signiﬁ-
cant reduction in astrogliosis in the QL6-treated group in the lesion
area (1.30 ± 0.17 for QL6; 2.58 ± 0.33 for control; P < 0.01) and in
perilesional areas (1 mm: 2.56 ± 0.18 for QL6; 3.15 ± 0.13 for con-
trol; P < 0.05) (Fig. 2C). Similarly, Iba1 immunointensity revealed
a signiﬁcant reduction of inﬂammation in the QL6-injected group
(control: 3.9 ± 0.24 vs. QL6: 2.95 ± 0.23) at the lesioned areas
(P < 0.05) (Fig. 2D).
3.3. QL6 attenuates post-traumatic apoptosis
Previous studies from our group have shown that apoptotic cell
death occurs as early as 6 h following SCI, peaks at 7 days and is
still evident at 14 days post-injury [27]. To determine the effects
of QL6 treatment on apoptotic cell death we used two marks of
apoptosis. TUNEL and activated caspase-3 immunostaining was
performed 1 week after injury. TUNEL- and caspase-3-positive cells
were found throughout the gray and white matter in the injured
spinal cord, with the greatest concentration close to the lesion site,
and a gradual decrease away from the epicenter. As shown in Fig. 3,
QL6 treatment was associated with a signiﬁcant reduction in
counts of TUNEL-positive cells at epicenter and on either side of
the lesion epicenter. Cleaved caspase-3 immunohistochemistry re-
vealed a similar result to TUNEL counts, but there was no signiﬁ-
cant difference between the two groups at 2 mm away from the
epicenter by caspase-3 quantiﬁcation. The mean ± SEM numbers
of apoptotic cells derived from control vs. QL6 injected animals
were: TUNEL: 127 ± 8.5 vs. 75 ± 8.7, caspase-3: 113 ± 5.6 vs.
74 ± 9.1 (epicenter); TUNEL: 100 ± 6.1 vs. 55 ± 6.7, caspase-3:
80 ± 7.1 vs. 59 ± 6.0 (1 mm) and TUNEL: 85 ± 5.2 vs. 52 ± 3.8, cas-
pase3: 66 ± 6.3 vs. 56 ± 4.2 (2 mm), respectively.
3.4. QL6 enhances tissue preservation at the lesion site
Eight weeks after SCI, spinal cord cross-sections were stained
serially with LFB-HE. Spinal cords from QL6-treated rats exhibited
a greater extent of spared tissue when compared to tissue sections
from the same location in the injured control rats (Fig. 4A). Mea-
surements of residual tissue taken from cross-sectional areas were
expressed as a percentage of the total cross-section area. A com-
parison of the percentages of normalized residual tissue, which is
represented in Fig. 4B, was performed by two-way ANOVA with
the two factors being treatment and distance from the injury epi-
center. This experiment revealed an overall signiﬁcant improve-
ment in tissue preservation in the QL6-treated group (P < 0.05).
The percentage of remaining tissue was 74.74 ± 4.12% in QL6-in-
jected animals and 61.05 ± 2.51% in control rats at 0.5 mm rostral
to the epicenter (P < 0.01). There was also a signiﬁcant increase
in the preserved neural tissue at 1 mm rostral to the epicenter
(82.93 ± 4.63% in the QL6-treated group vs. 70.63 ± 4.32% in the
control group; P < 0.05). However, there was no marked difference
observed in tissue preservation in the caudal region between two
groups. This could be due to different vascular injury and recovery
at rostral vs. caudal regions in our SCI model.
Fig. 2. QL6 leads to reduced astrogliosis and inﬂammation in chronic SCI. Photomicrographs showing a transverse section of rat spinal cord stained with GFAP (A) and Iba1 (B)
in control and QL6-injected animal. There is less astrogliosis and inﬂammation in the QL6-injected animals. Scale bar: 250 lm for (A) and (B). 8 weeks after SCI, GFAP (C) and
Iba1 (D) immunoﬂuorescence levels in the QL6-injected animals are signiﬁcantly reduced compared with control animals. Data are mean ± SEM (bars) values, n = 6 per group;
⁄⁄P < 0.01, ⁄P < 0.05. Images were taken from the injury epicenter.
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counts of neurons retrogradely labeled by ﬂuorogold
The corticospinal tract (CST) consists of axons from pyramidal
neurons originating in the motor cortex extending to the contralat-
eral spinal cord. It represents the primary transmission tract for
brain-controlled voluntary movement. To investigate whether the
SAP QL6 could promote axonal sparing in the chronically injured
spinal cord, we examined the plasticity of CST collaterals innervat-
ing the spinal cord using anterograde BDA labeling. Notably, we
observed an increase in BDA-labeled ﬁbers in the dorsal funiculus
of the contralateral spinal cord in the QL6-injected group com-
pared with the control group (Fig. 5A). Quantitative analysis of
the BDA tracing regions revealed a signiﬁcant increase in the den-
sity of BDA-labeled collaterals in the QL6-injected rats when com-
pared to the injured controls at all distances (ranging from 2 to
8 mm) rostral to the lesion with the highest value detected at
4 mm (a 1.63-fold increase) (Fig. 5B). However, no evidence of
long-distance CST axon preservation/regeneration at and beyond
the lesion was detected (data not shown).
The survival of axons traversing the injury site was also as-
sessed by counting the FG-labeled neurons in brainstem nuclei fol-
lowing spinal cord transection and FG impregnation distal (T10) to
the injury site. Counts of retrogradely labeled neurons were per-
formed in the red nucleus, vestibular nuclei and the total brain-
stem (which includes red nucleus, vestibular nuclei, raphe nuclei
and reticular formation). Representative sections of FG-labeledneurons in the red nucleus from animals treated with saline and
QL6 are shown in Fig. 5C. QL6-injected animals showed higher
overall neuronal counts in the red nucleus, vestibular nuclei and
total brainstem (Fig. 5D). The number of labeled neurons was sig-
niﬁcantly higher in the red nuclei (665.38 ± 51 for control vs.
856.27 ± 42 for QL6; P < 0.05) and total brainstem (4830.15 ± 498
for control vs. 6767.80 ± 422 for QL6; P < 0.05) in the QL6-injected
group. The numbers of labeled neurons from QL6-injected animals
in the vestibular nuclei (545.13 ± 57 for control vs. 768.45 ± 96 for
QL6; P = 0.09) was not signiﬁcantly different from those in saline-
treated controls.
3.6. Evaluation of NPC differentiation within the QL6 SAP scaffolds
We have shown convincing data that illustrate the ability of QL6
scaffold to inhibit astrogliosis while markedly enhancing axonal
density. After SCI, neurogenesis is largely mediated by endogenous
stem cell differentiation, which produces several cell types includ-
ing neurons and glia. To further understand the differential capa-
bility of QL6 in promoting neuronal and astroglial growth, we
examined the effects of QL6 on the differentiation capability of
NPCs into neurons and astroglial, respectively. As shown by immu-
nocytochemistry (Fig. 6A), the QL6 nanoﬁber scaffold promoted
greater differentiation of the NPCs into neurons, and suppressed
astrocytic differentiation when compared with the matrigel con-
trol. In agreement with our previous study [19], we found that
when cultured on matrigel with 1% FBS, neurons represented
Fig. 3. QL6 administration reduced post-traumatic apoptosis after SCI. (A) Representative sections from a QL6-injected and control animal respectively immunostained with
TUNEL and cleaved caspase-3 at 1 week after SCI. Section stained with TUNEL in green, caspase-3 in red and nuclear marker DAPI in blue; scale 40 lm. A reduction of TUNEL-
and caspase-3-positive cells was observed in the QL6-injected group. (B) Bar graph showing that there was a signiﬁcant decrease in TUNEL- and caspase-3-positive cell death
in the QL6 treatment group vs. control group Values are mean ± SEM, n = 6 per group; ⁄⁄P < 0.01; ⁄P < 0.05.
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the neuronal marker bIII-tubulin, while astrocyte lineage cells
were the major cell type observed with 64 ± 2.2% of the cells stain-
ing positively for GFAP because serum composition favors astro-
cyte speciﬁcation. In contrast, there were about 14 ± 0.9% of total
cells staining positive for bIII-tubulin and 33 ± 1.6% astrocyte dif-
ferentiation cultured on QL6 nanoﬁber network for 7 days
(Fig. 6B). Inhibition of astrocyte proliferation is believed to be
important in the prevention of the glial scar, a known barrier to
axon elongation.3.7. QL6 treatment enhances MEPs
After QL6 injection, we observed increased axon preservation.
These studies suggested that the conduction capability of the
spinal axons could be improved in the treatment group. To test this
hypothesis, we recorded MEPs from both injured control and QL6-
injected groups. At 8 weeks post-SCI both the treated and controlgroups of rats displayed a biphasic deﬂection pattern. QL6-treated
animals had signiﬁcantly higher peak amplitude compared to the
injured control animals. The peak amplitude of the QL6-treated
animals was 5.46 ± 1.29 lV while the control rats had an ampli-
tude of 1.79 ± 0.41 lV (P < 0.05). Latency was also shorter in the
treated group compared to control animals, indicating a faster con-
duction velocity in the QL6 group. The peak latency of the control
group was 25.97 ± 2.12 ms while the QL6-treated animals had a
signiﬁcantly shorter latency of 20.03 ± 1.48 ms (P < 0.05) (Fig. 7).3.8. QL6 treatment enhances the electrophysiological properties of
dorsal column axons in isolated ex vivo recordings
CAP recording from the dorsal column of the spinal cord pro-
vides a further readout of functional recovery after QL6 treatment.
We ﬁrst characterized the amplitude of the CAPs, since CAP ampli-
tude is directly associated with the number of axons available to
carry nerve pulses. The axonal conduction properties were exam-
Fig. 4. QL6 improves spinal cord tissue preservation. (A) Representative sections taken 0.5 mm rostral to the epicenter from a QL6-treated and saline control animal
respectively stained with LFB and HE (scale bar: 300 lm) 8 weeks after SCI. QL6-treated spinal cord exhibited a larger extent of spared tissue than control animal tissue. (B)
Per cent normalized residual tissue in QL6 treatment (j) vs. control () group. There was a signiﬁcant different between QL6-treated animals vs. controls by two-way ANOVA
with post hoc (Bonferroni) test. ⁄P < 0.05 and ⁄⁄P < 0.01: signiﬁcantly increased tissue area in QL6-treated animals at different distances from injured epicenter. Data are
mean ± SEM (bars) values (n = 10 per group).
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suprathreshold stimulus. We found that the CAP amplitude was
signiﬁcantly larger in the QL6-treated cords than in the injured
cords (3.23 ± 0.82 mV vs. 0.97 ± 0.03 mV; P < 0.05—see Fig. 8A).
Previous studies have reported that the refractory period of ax-
ons is increased after SCI [24]. Here, we investigated whether QL6
injection can alleviate axonal refractoriness after SCI. To assess the
refractoriness of the spinal cord, paired stimuli with varied inter-
vals were delivered to the cord, and we measure the minimum
time intervals for the second pulse to trigger CAP (absolute refrac-
tory period), as well as the full recovery of the CAPs (relative
refractory period). Varying the intervals between the two paired
pulses successfully yielded a clear estimation of the absolute
refractory periods. We observed a signiﬁcant decrease (P < 0.01)
in the absolute refractory period in the QL6-treated groups in com-
parison to the injured control (Fig. 8B). Similarly, QL6-treated cords
also exhibited a decreased relative refractory period (Fig. 8C). Ta-
ken together, these data indicate that QL6 treatment signiﬁcantly
reduces axonal refractoriness in injured cords.
3.9. QL6 treatment improves high-frequency conduction
Previous studies have shown that axonal responses to high-fre-
quency signals were compromised after SCI [24]. Hence, we tested
if QL6 injection could rescue impaired HFS responses in the chronic
SCI. We stimulated the cords with trains of repetitive stimuli com-posed of frequencies of 20, 50 and 100 Hz (100 pulses in total).
Similar to previous publications [24,28], quantiﬁcation analysis of
frequency response was performed by analyzing the ‘‘fatigue ratio’’
of the axons, which was expressed as the ratio between the ampli-
tude of the 100th CAP in the train as a percentage of the ﬁrst ampli-
tude of the ﬁrst CAP. A higher ratio suggested a better axonal
response to high-frequency stimulation. Fig. 9A shows an example
of CAP changes in responses to 100 Hz stimulation in the injured
cord, and in injured cord treated with QL6. Fig. 9B plots the ampli-
tude of the CAP correspondence to the 100 Hz stimulus. QL6 injec-
tion prevented the dramatic decrease in the CAPs that was
otherwise observed in the injured cords.
We also attempted other stimulation frequencies, including
20 Hz and 50 Hz. In accordance with previous studies [21], the
CAP100/CAP1 ratio decreased in the injured cords in response to in-
creased stimulation frequencies (P < 0.001). Overall, after QL6
injection, the injured cords were associated with a much higher
CAP100/CAP1 ratio compared to those of the control injured cords
(P < 0.001, two-way ANOVA), and this difference reached statistical
signiﬁcance at 20 Hz (73.8 ± 4.7 in injured cords vs. 93.5 + 2.3% in
QL6-treated cords; P < 0.01), 50 Hz (67.2 + 2.0% in injured cords
vs. 86.1 ± 1.9% in QL6-treated cords; P < 0.001) and 100 Hz
(51.1 + 2.5% in injured cords vs. 81.7 + 1.5% in QL6-treated cords;
P < 0.001). Combined, these results suggest that the QL6 injection
reduced the ‘‘fatigue ratio’’ in the injured spinal axons, and im-
proved the high-frequency conduction of the axons.
Fig. 5. QL6 promotes axonal preservation by BDA anterograde (A, B) and FG retrograde (C, D) tracing. (A) Representative sections from a QL6-injected and control animal
BDA-labeled CST. Images in the right panels (scale bar: 50 lm) show the enlarged boxes in the left panels (scale bar: 300 lm). (B) 8 weeks after SCI, analysis revealed a
signiﬁcant increase in the density of BDA-labeled ﬁbers in the QL6 treatment group when compared to the injured control group at 2, 4 and 8 mm rostral to the lesion center.
(C) Fluorescent photomicrographs of FG-labeled neurons in the red nucleus in animals treated with either QL6 or saline. (D) There were signiﬁcantly higher numbers of
neurons in the red nucleus and brainstem nuclei in QL6-treated animals. Scale bar: 40 lm. Data are mean ± SEM values, n = 6 per group; ⁄P < 0.05.
Fig. 6. Immunocytochemistry of NPCs cultured for 7 days in vitro on QL6 peptide scaffold or matrigel. (A) Differentiated neurons were labeled for bIII-tubulin (green), and
differentiated astrocytes were labeled for GFAP (red). All cells were DAPI stained (cell nuclei in blue). The QL6 SAP displayed the capability to support differentiation of
neurons while suppressing astrocyte differentiation compared to the matrigel control. (B) Percentage of total cells that differentiated into neurons and astrocytes. QL6 gave
signiﬁcantly higher percentages of differentiated neurons and lower percentages of differentiated astrocytes than those obtained with matrigel. Scale bar: 30 lm. Data are
mean ± SEM values; ⁄⁄P < 0.001.
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Fig. 7. At 8 weeks post-SCI, QL6 treatment resulted in signiﬁcantly higher peak amplitude and shorter latency, indicating a greater preservation of motor function. (A)
Representative MEP tracings from hindlimb muscle of QL6-treated animal and injured control animal where S denotes the stimulus artifact and N1 indicates the ﬁrst
prominent negative peak. (B) Quantitative analysis of peak latency and amplitude. The MEP amplitude was larger in QL6-treated animals compared to injured control rats.
MEP latency was shorter in QL6 rats compared to injured control rats. Data are mean ± SEM values, n = 6 per group; ⁄P < 0.05.
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To examine the functional effects of injecting SAP QL6 after SCI,
neurobehavioral function was assessed weekly by two blinded
observers using the BBB locomotor rating scale. Acutely, the hind
limbs of experimental animals were completely paralyzed after
SCI. Hind-limb performance gradually improved in both experi-
mental groups. The mean BBB scores (Fig. 10) of QL6-injected ani-
mals were higher than those of saline-treated controls at every
week. Using two-way repeated measures ANOVA, we found an
overall signiﬁcant improvement on BBB scores in the QL6-treated
group (P = 0.03). At 6 weeks, the saline control rats reached an
average score of 6, indicating non-functional movement of the
three hind-limb joints without coordinated sweeping of their hind
legs. In contrast, the QL6-treated rats reached an average score of 8,
indicating the ability to make sweeping movements with their
hind legs or coordinated plantar placement of the hind limbs with-
out weight support. There was little further relative improvement
in both experimental groups at weeks 7 and 8, suggesting a plateau
in neurological recovery had been reached at week 6.
4. Discussion
The present study shows that SAP QL6 injection leads to de-
creased apoptosis, inﬂammation and glial scarring, and enhanced
tissue preservation at the site of injury. QL6 improved axonal con-
duction as indicated by increased peak amplitude and decreasedpeak latency. QL6 also increased high-frequency conduction and
reduced the refractoriness in the injured cords. This was mani-
fested by signiﬁcant improvement in locomotor function on the
BBB scale. Taken together, these data suggest that SAP QL6 is an
attractive therapeutic strategy for SCI as it preserves axons, trans-
lating to better functional outcomes. Our data demonstrated that
the SAP QL6 is a prospective biomaterial for the reconstruction of
the injured spinal cord.
4.1. Biocompatibility of QL6
The use of a nanoﬁber scaffold is a novel approach in providing
extracellular matrix-like structures that are potentially conducive
to cellular inﬁltration, proliferation, tissue repair and regeneration
[29]. The QL6 peptides are characterized by periodic repeats of
alternating ionic hydrophilic and hydrophobic amino acids (gluta-
mine and leucine, respectively). QL6 shows a very strong b-sheet
conformation and a population of nanoﬁbers with uniform diame-
ter (6 ± 1 nm) and controlled length (120 ± 30 nm). The maximum
QL6 ﬁber lengths have not changed substantially but the average
lengths increased slightly, owing to the disappearance of shorter ﬁ-
bers 3 weeks after assembling. Other methods, including circular
dichroism and Fourier transform infrared spectrometry, did not re-
veal any signiﬁcant changes over time [11]. Therefore, QL6 struc-
ture could be relatively stable in vitro after assembling. After
injection as a liquid, QL6 demonstrated the ability to mimic the
exctracellular matrix and became conducive to tissue repair/regen-
Fig. 8. Ex vivo electrophysiology. CAP recordings were performed 8 weeks after SCI. (A) QL6-treated cord is associated with a greater amplitude in CAP. (B) QL6 injection
reduced the absolute refractory period in the injured cords. (C) QL6 injection reduced the relative refractory period in the injured cords. Pair-pulse protocol with different
intervals was used to detect the absolute refractory period (B) and relative refractory period (C) in the injured cords and in QL6-treated cords. Note (C) depicts the overlapped
traces with increment stimulating intervals. Data are mean ± SEM values, n = 6 per group; ⁄⁄P < 0.01.
Fig. 9. Effects of QL6 treatment on axonal responses to high-frequency stimulation 8 weeks after SCI. The cords were stimulated with trains of 100 stimuli (0.1 ms in width) at
varying frequencies (20, 50, 100 Hz). (A) CAPs evoked by a train of stimulus (100 Hz) in an injured cord and in a QL6-treated cord. Shown here are the 1st response and the
100th response. (B) Percentage changes in the amplitude of CAPs as a function of the number of pulses in an injured control cord and in a QL6-treated injured cord. (C)
Frequency dependency of CAPs in injured cords and in QL6-treated injured cords at 20, 50 and 100 Hz, respectively. Note that injury-induced deﬁcits in the high-frequency
conduction were partially prevented with QL6 treatment (P < 0.001). ⁄P < 0.01; ⁄⁄P < 0.001.
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such as peptide amphiphile (PA), alone were not sufﬁcient in neu-
rite sprouting and differentiation [30]. It was necessary to promotePA bioactivity by incorporating the neurite-promoting laminin epi-
tope IKVAV into the molecular design of the scaffold [7]. This study
shows that the structure of QL6 itself, without any pharmacologi-
Fig. 10. The graph depicts functional hind-limb recovery over time after SCI.
Injection with QL6 resulted in improved BBB scores vs. controls at week 1 through
week 8. Two-way ANOVA conﬁrmed a signiﬁcant (P = 0.03) difference between the
two groups. Data are mean ± SEM values, n = 23 per group.
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that might be related to QL6’s direct action in attenuating glial
scarring and post-traumatic inﬂammation. It is interesting to note
that the soluble form of QL6 has a pH value of 7, which is able to
acclimatize to the microenvironment of the host and may be more
suitable for the cell entrapment and growth. The physiological pH
value in the spinal cord in rat is about 7.4 [31]. However, mild sys-
temic acidosis could occur within hours after SCI and the pH value
may decrease [32]. We injected the material 24 h after the injury, a
time point by which the pH in the injured tissue has returned to
normal physiological conditions [31]. We found that the QL6 in-
jected directly to the injured spinal cord yielded positive neuroana-
tomic and neurophysiological results. We did not observe acute
systemic or local toxicity effects, as shown by our results acquired
1 week after QL6 injection, suggesting that using SAP QL6 with
intrinsic pH close to physiological values could yield excellent bio-
compatibility, which may be critical for providing a microenviron-
ment for cell–scaffold interaction.4.2. Effects of SAP in alleviating SCI pathology and its possible
mechanisms
The current lack of effective therapeutic options for curing SCI is
due to the complexity of the pathophysiological events that occur
after this trauma. These unfavorable events include inﬂammation,
cell death, demyelination, axonal degeneration, and the formation
of cavities that are initially lined by reactive gliosis and, subse-
quently, by glial scars [33,34]. The present results show that SAP
QL6 scaffolds serve as a bridge to prevent the collapse of adjacent
tissue, and alleviate the pathology of secondary injury including re-
duced apoptosis, inﬂammation, glial scarring and subsequent cyst
formation. The decreased apoptosis and astrogliosis are correlated
with a higher degree of tissue preservation at the injury site, and
functional recovery.
The precise mechanisms for the effects of SAP are not yet
known but our in vitro study of QL6 SAP culture and some previous
ﬁndings may shed light on the potential mechanisms. It has been
shown that, in vitro, the outer scaffold formed by the SAP can inhi-
bit the ingrowth of a variety of cell types, including ﬁbroblasts, into
the porous scaffold [35]. This may reduce inﬂammatory cell inﬁl-
tration after SCI, in turn reducing astrogliosis. As observed in our
study, QL6 can signiﬁcantly suppress astrocytic differentiation of
cultured NPCs. Therefore, it is hypothesized that the SAP scaffold
may impede scarring and subsequent cyst formation by suppress-
ing cellular ingrowth through the outer scaffold. Histological anal-
ysis of the spinal cord tissues showed the reparative processes
fostered by the presence of SAP QL6-based scaffold in the lesion
site.
Of note, SAP QL6 signiﬁcantly increased the axonal density in
the CST in regions rostral to the injury center. Counts of FG-labeledneurons in brainstem nuclei revealed a statistically signiﬁcant
improvement with QL6 treatment in axonal survival of rubrospinal
and total brainstem neurons. The observed increase in axonal den-
sity may be attributed to enhanced axonal preservation and/or ax-
onal sprouting, leading to the conclusion that the biocompatible
scaffold could preserve or attract nerve ﬁbers and potentially ame-
liorate the locomotor recovery of SCI. We propose the following
two explanations for the axonal preservation and/or regeneration.
First, our in vitro data show that QL6 can direct the differentiation
of neural precursor cells into neurons. This result is in agreement
with several previous studies in which nanoﬁbers were found to
promote outgrowth of processes from cultured neurons and sup-
press astrocytic differentiation of cultured neural stem cells
[30,36,37]. It is possible that QL6 promotes an exaggerated effect
on neurite production. Second, in fact, macrophage activity has
been found to induce axonal retraction/die-back in the sensory ax-
ons [38], as has glial scarring [33]. In the injured brain, SAPs have
been found to reduce the glial reaction and inﬂammation in the
surrounding brain tissue [9]. Recently, it has been reported that
nanoﬁbers exhibited cytoprotective and anti-inﬂammatory prop-
erties in vitro and in vivo [39]. Therefore, it is possible that the ef-
fect of SAPs in preserving axons is via their capability to inhibit
glial scar formation and reduce inﬂammation. Further studies are
underway to clarify the cellular molecular mechanisms underlying
the action of QL6.
4.3. Functional assessment of QL6 effects with electrophysiological and
neurobehavioral tests
The use of SAP QL6 nanoﬁber scaffold remarkably promoted ax-
onal preservation and/or sprouting as shown by tract tracing tech-
niques. This could play a major role in modulating various
neuronal activities, including the conjoint increase in conduction
velocity and locomotion, since functional recovery can be signiﬁ-
cantly enhanced even if a small amount of normal tissue survives
[40]. To test this hypothesis, we implemented in vivo and ex vivo
electrophysiological experiments and behavioral assessment with
BBB score, which provided a complementary strategy to monitor
therapeutic interventions in this SCI research. To the best of our
knowledge, systematic in vitro and in vivo electrophysiological
investigation testing the effects of SAPs has been missing from
the literature to date. SCI generally causes decreased amplitude
in CAPs in white matter axons [22]. The mechanism behind this in-
volves the reduced number of physically intact axons, reduced ax-
onal excitability, channel density and activation. Our histological
data indicate that more axons were preserved in the QL6-treated
group, potentially explaining the larger-amplitude MEP and CAPs
recorded from the treated cords.
Previous studies also show that the refractoriness of axons in-
creases after SCI, behavior that is mainly related to the selective
survival of smaller diameter axons [24]. Alternatively, it may be
that SCI-induced demyelination causes low axonal membrane
capacitance and impairs its fast depolarization and repolarization,
thus causing increased refractoriness. Our data show refractoriness
is decreased after QL6 injection. It is therefore interesting to eval-
uate the above two possibilities, in order to tease out the funda-
mental cellular mechanisms underlying nanomaterial treatment
in chronic SCI.
SCI is associated with a decreased axonal response to high-fre-
quency stimulation in the injured cords. This decreased capability
of axons to propagate action potentials at high frequency is be-
lieved to be associated with reductions in the myelin sheath, which
compromises the membrane capacitance needed for normal action
potential propagation in the surviving myelinated axons [24].
The fact that QL6 can enhance high-frequency conduction indicates
that the biomaterial may have certain beneﬁcial effects in
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ated axons. It has been observed that self-assembly nanoﬁbers
could cause an increase in the number of oligodendrocytes in the
injured spinal cord [7] and the increased number of oligodendro-
cytes at the site of injury could facilitate remyelination of axons
that traverse the lesion [41,42]. Therefore, it is possible that QL6
will alleviate these impairments after SCI by enhancing remyelina-
tion to the spared, demyelinated axons around the epicenter.
5. Conclusions
In summary, the present study indicates that SAP QL6 nanoﬁ-
bers induced favorable reparative processes, and provides evidence
that neural repair after SCI could be accomplished by the applica-
tion of a synthetic, biocompatible, scaffolding material without
including bioactive sequences in the SAP. Although the QL6 scaf-
fold appears to play a signiﬁcant role in functional recovery follow-
ing SCI, one possible weakness of this biomaterial is the lack of
neurons or neuroﬁbers in the grafted scaffold [9,43]. In order to
overcome this obstacle, we are investigating improved strategies
to further utilize the features of this scaffold, such as using it in
combination with neural stem cells or growth factors, for subacute
and chronic SCIs in which repair is highly challenging. This combi-
natorial approach using SAP QL6 will be critical to achieve the
greatest recovery, and may constitute a promising biocompatible
scaffold approach for regenerative applications in the injured cen-
tral nervous system. It is hoped this will eventually lead to the
development of effective experimental therapies in humans.
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Appendix A. Figures with essential colour discrimination
Certain ﬁgures in this article, particularly Figs. 1–6 and 9, are
difﬁcult to interpret in black and white. The full colour images
can be found in the on-line version, at http://dx.doi.org/10.1016/
j.actbio.2013.06.001.
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